Didn't register yet? Don't miss the CAR-T day

New #EHAUnplugged episode available now - Managing Young Fit AML patients. President of EHA, Prof Konstanze Döhner, discusses the most recent developments in the management of young and fit patients with AML. Hear about the diagnostic workup, risk stratification, treatment, and

I was lucky to lead this CIBMTR analysis just published in AmericanJournalofHematology 👇 onlinelibrary.wiley.com/share/author/4… 🔑 findings: 💡 CD19 CAR T-cell therapy leads to high rates of durable responses in patients with primary mediastinal large B-cell lymphoma (PMBCL): ORR 79% CRR 68% 2-year PFS

Congratulations to all the co-authors, specially to DrDonalMcLornan and Mette Hazenberg for their leadership and perseverance! The future is bright! 🎉🎉🎉🎉

Honoured to speak today #ACTO2025 the 16th #ACTO Annual Meeting in Singapore. Describing the GoCART_Coalition vision, mission & activities to foster the development and access to #CART Cells therapies in Europe EBMT European Hematology Association Jurgen Kuball JACIE Anna Sureda

Patients with relapsed or refractory primary or secondary CNS lymphoma face a poor prognosis. This study of 100 patients treated with anti-CD19 CAR T-cell therapy showed promising results, supporting its use for these patients despite the risk of severe neurotoxicity. Read

The last CIBMTR EBMT publication! #ICOnic Anna Sureda participation! ashpublications.org/blood/article/…

🎉 Celebrating the anniversary of the EBMT Registry Since the current system went live in August 2023: 📊 65,000+ new patients added 📈 790,000+ total patient records 💡 73,400+ treatments registered Thank you to our community for making this possible! 🌍 Read more about the

📣 Register early and submit your abstract for #EBMT26 – join us in Madrid for Europe’s largest congress in #HCT and #CellTherapy. 📽️ Hear the welcome from Rafael Duarte and Isabel Salcedo 📌 Check out Early Bird discounts, and 🌍 Get ready to connect with 6,200+ colleagues from

Gamma delta (γδ) T cells, constituting 5%–10% of peripheral blood lymphocytes, are pivotal in tumor immunosurveillance and are enriched in epithelial tissues. Their unique antigen recognition makes them ideal for allogeneic cell therapy products, with several clinical trials

A World First in Hematology Education ⁦IACH⁩ is proud to announce the first-ever AI-generated live webinar in hematology. Harnessing the power of AI, this event will deliver a glimpse into the future. Join us at this historic milestone where innovation meets hematology.

Let’s cut it out - HIV from cells CRISPER ly

🗓️ The 3rd Practice Harmonisation and Guidelines Committee meeting took place in Berlin end of September, bringing together experts from across Europe and beyond. 🌐 With: 👩‍🏫 12 parallel workshops 👥 100+ participants from 🌍 22 countries, This event fostered collaboration,

#Badinter #Panthéon «Le fascisme ne se lève pas comme la tempête en une nuit. D’abord rampant, dissimulé, ordinaire, il progresse par les voix de la haine, avivée par les difficultés économiques. Il s’empare des cœurs avant de pervertir les esprits puis de prendre le pouvoir»☝️

🏆𝘁𝗵𝗲 𝗜𝗔𝗖𝗛 𝟮𝟬𝟮𝟱 𝗔𝘄𝗮𝗿𝗱 𝗖𝗲𝗿𝗲𝗺𝗼𝗻𝘆 𝘛𝘩𝘦 𝘳𝘦𝘤𝘪𝘱𝘪𝘦𝘯𝘵 𝘰𝘧  𝘁𝗵𝗲 𝗖𝗵𝗿𝗶𝘀𝘁𝗶𝗮𝗻 𝗖𝗮𝗶𝗹𝗹𝗶𝗼𝘁 𝗖𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗥𝗲𝘀𝗲𝗮𝗿𝗰𝗵 𝗔𝘄𝗮𝗿𝗱 is 𝗣𝗿𝗼𝗳. 𝗔𝗻𝗻𝗮𝗹𝗶𝘀𝗮 𝗥𝘂𝗴𝗴𝗲𝗿𝗶 𝘊𝘰𝘯𝘨𝘳𝘢𝘵𝘶𝘭𝘢𝘵𝘪𝘰𝘯𝘴! Mohamad Mohty Arnon Nagler

🧬 We unite with key stakeholders across the European healthcare ecosystem to safeguard the #HospitalExemption for Advanced Therapy Medicinal Products (ATMPs). 📣 This Joint Position Statement puts forward the key recommendations to secure a fair, balanced, and effective

📘 Coming soon: A major milestone for the #HCT and #CellularTherapy community! The new FACT-JACIE International Standards (HCT 9 and IEC 3) mark three years of global collaboration to advance quality, safety and best practice in cellular therapies. ⬇️ ebmt.org/ebmt/news/fact…

🔍 FACT-JACIE Standards require alignment across Clinical, Collection, and Processing Units (B1.2 & C1.2). ☑️ All participating units must operate under certified conditions to ensure the highest standards of patient care and safety. 💡 Read more: ebmt.org/ebmt/news/ensu…

Celebrating 35 years of academic excellence! The IFM has led groundbreaking trials shaping the modern era of high-dose therapy in myeloma. Proud to see this legacy highlighted in ⁦Blood Cancer Journal⁩ , showcasing how IFM research has set global standards for myeloma care.

📢 Now available: Foundation for Accreditation of Cellular Therapy and #JACIE 9th Edition HCT Standards + 3rd Edition IEC Standards! 👏 A key milestone and example of the ongoing commitment to promoting high quality and patient safety in #HCT and #CellularTherapy worldwide. ⤵️  📌 ebmt.org/ebmt/news/fact…